Endothelial progenitor cells for pulmonary hypertension
The purpose of this study is to assess the feasibility, safety, and initial clinical outcome of intravenous infusion of autologous endothelial progenitor cells (EPCs) to patients with pulmonary hypertension. So far, treatment has been well tolerated. Importantly, the pulmonary resistance did not show any increase after treatment, rather, there appeared to be a substantial decrease over the 3 days of cell delivery. There was also an improvement in 6-minute walk distance. After a period of three months, this improvement declined back to the original state, indicating that treatment would likely need to be repeated over time.
Read More
Product Information for
Endothelial progenitor cells for pulmonary hypertension
Links related to the product - may include a range of information sources (e.g., press releases, websites, patents) related to the specific cell therapy application.
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access